SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Trading Update

28 Apr 2011 14:08

RNS Number : 6666F
Tristel PLC
28 April 2011
Β 

ο»Ώ

Β 

28th April 2011

Tristel plc

("Tristel" or "the Company")

AIM: TSTL

Β 

Trading Update

License Delays and Trading Update

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that as a consequence of delays in receipt of the licence to sell its Stella tray system in China and the delay in securing inclusion of its Wipes System on Germany's VAH listing, a substantial portion of revenues originally anticipated to fall in its current financial year will now be deferred to the financial year commencing 1 July 2011. The Company's planned expansion into the Pharmaceutical and Personal Care market with its "Crystel" range of disinfectants and cleaning products has also had a slower start than anticipated.

Whilst the Company is confident that the license delays referred to above will be successfully concluded, it is unlikely that Germany and China will make the positive contribution to the current year's result originally anticipated. Therefore, the Company now anticipates results for the second half will be at least break-even (pre-IFRS 2 charge) delivering a full year pre-tax profit of no less than Β£433,000.

In line with its expansion plan, the Company has continued to invest in sales and manufacturing infrastructure and the second half result is, therefore, bearing a much enlarged cost base. The Company remains debt free and will continue with its expansion plan as detailed in the interim results. Significant growth is anticipated in 2012 and beyond.

For further information, please contact:

Tristel plc

Β 

Paul Swinney, Chief Executive

Tel: 01638 721 500

Β 

Β 

finnCap

Β 

Geoff Nash / Charlotte Stranner (Corporate Finance)

Tel: 020 7600 1658

Β 

Β 

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Enquiries)

Mob: 07917 575 484

Β 

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Enquiries)

DD: 020 7933 8794

Β 

paul.cornelius@walbrookir.com

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTXVLFLFZFBBBD
Date   Source Headline
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding
5th Apr 20222:45 pmRNSDirector/PDMR Shareholding
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.